Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

DUSA PHARMA Form 4	ACEUTICALS	INC								
May 12, 2008										
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								2235-0287	
if no longer subject to Section 16. Form 4 or		NT OF CHAN	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Expires: January 31 2005 Estimated average burden hours per response 0.5	
Form 5 obligations may continue. See Instruction 1(b).	Section 17(a)	ant to Section 16 of the Public Ut 30(h) of the Inv	ility Holdi	ing Comp	pany	Act of	f 1935 or Sectio		0.5	
(Print or Type Respo	onses)									
1. Name and Addre LUNDAHL SC	Symbol DUSA F	2. Issuer Name and Ticker or Trading Symbol DUSA PHARMACEUTICALS INC [DUSA]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) C/O DUSA PHA INC., 25 UPTO		(Month/Da	-	nsaction			Director X Officer (give below) VP, Regu		o Owner er (specify & IP	
WILMINGTON	Filed(Month/Day/Year) A				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State) (Zip	^{o)} Table	e I - Non-De	erivative So	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
		A. Deemed	3. Transactio Code (Instr. 8)	4. Securiti	es Aco posed	quired of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common 05	/09/2008		Code V A	Amount 11,000 (1)	(D) A	Price \$ 0	(Instr. 3 and 4) $11,000 (1)$	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 2.2	05/09/2008		А	16,500 (2)	05/09/2009	05/09/2015	Common Stock	16,500

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
LUNDAHL SCOTT L C/O DUSA PHARMACEUTICALS, INC. 25 UPTON DRIVE WILMINGTON, MA 01887			VP, Regulatory Affairs & IP				

Signatures

Reporting Person

/s/ Scott L. Lundahl 05/09/2008 **Signature of

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Stock Awards vest at the rate of one-quarter of the total grant on each of the first, second, third and fourth anniversaries of the date of (1) grant.
- (2) Options vest at the rate of one-quarter of the total grant on each of the first, second, third and fourth anniversaries of the date of grant.

Remarks:

See attached footnote page.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.